Janus kinase inhibitors: between prescription authorization and reimbursability

Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.

Bibliografiska uppgifter

Huvudupphov:	F.R. Spinelli, F. Conti, R. Caporali, F. Iannone, F. Cacciapaglia, on behalf of the Steering Committee of the Italian Society of Rheumatology
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	PAGEPress Publications 2023-12-01
Serie:	Reumatismo
Ämnen:	Janus kinase inhibitors
Länkar:	https://www.reumatismo.org/index.php/reuma/article/view/1627
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!